;

Auto Summaries - Drug
Last updated: 2024 Oct 18
Total hit(s): 6797
S.No.
1
39321502
Corrigendum to "The significance of recurrent de novo amino acid substitutions that emerged during chronic SARS-CoV-2 infection: an observational study" [eBioMedicine, 2024;107:105273].
N/A
EBioMedicine
2024 Oct
6.49
1
2
39341219
Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination.
N/A
Lancet Infect Dis
2024 Sep 25
21.77
1
3
39164256
Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection.
N/A
Signal Transduct Target Ther
2024 Aug 21
- n/a -
1
4
38980939
Impact of coronavirus disease 2019 monoclonal antibodies on outcomes of coronavirus disease 2019 infection in hematopoietic stem cell transplant and chimeric antigen receptor therapy recipients.
N/A
Transpl Infect Dis
2024 Jul 9
2.04
1
5
39083043
Features of the SARS-CoV-2 KP.3 variant mutations.
N/A
Infect Dis (Lond)
2024 Jul 31
1.23
1
6
38961696
Is there an increased number of community-acquired pneumonia requiring drainage placement in children after COVID-19 pandemic in Italy?
N/A
Pediatr Pulmonol
2024 Jul 3
2.64
1
7
39002189
Design and fabrication strategies of molybdenum disulfide-based nanomaterials for combating SARS-CoV-2 and other respiratory diseases: A review.
N/A
Biomater Adv
2024 Jul 3
1
8
39041943
Validating combination throat-nasal swabs for COVID-19 tests would improve early detection, especially for the most vulnerable.
N/A
Clin Infect Dis
2024 Jul 23
7.71
1
9
39041264
Unveiling the Role of SARS-CoV-2 or mRNA Vaccine Spike Protein in Macrophage Activation Syndrome (MAS).
N/A
Infect Disord Drug Targets
2024 Jul 22
1.5
1
10
39030295
Deletion of V483 in the spike confers evolutionary advantage on SARS-CoV-2 for human adaptation and host-range expansion after a prolonged pandemic.
N/A
Cell Res
2024 Jul 19
10.9
1
11
38809158
Another variant another history: description of the SARS-CoV-2 KP.2 (JN.1.11.1.2) mutations.
N/A
Infect Dis (Lond)
2024 Jul
1.23
1
12
38937220
A case of generalized pustular psoriasis following Moderna/NIAID COVID-19 vaccination successfully treated with secukinumab.
N/A
An Bras Dermatol
2024 Jun 26
1
13
38960856
The experience of pregnant women and their families who were infected with covid-19 before vaccination: Comment.
N/A
Midwifery
2024 Jun 21
4.3
1
14
38734020
Additional SARS-CoV-2 vaccine doses: a little is better than none.
N/A
Lancet Rheumatol
2024 May 8
- n/a -
1
15
38713760
Correction to "Exploration of SARS-CoV-2 3CL(pro) Inhibitors by Virtual Screening Methods, FRET Detection, and CPE Assay".
N/A
J Chem Inf Model
2024 May 7
4.04
1
16
38803053
Active vitamin D analog and SARS-CoV-2 IgG after BNT162b2 vaccination in patients with hemodialysis: Correspondence.
N/A
Ther Apher Dial
2024 May 27
2.7
1
17
38664266
Correction: Detection of SARS-CoV-2 spike protein D614G mutation using muTGGE.
N/A
Mol Biol Rep
2024 Apr 25
2.19
1
18
38607273
The mouse to man conundrum: Revisiting an old lung injury model to study repurposed drugs for COVID-19 treatment.
N/A
Exp Physiol
2024 Apr 12
4.3
1
19
38511965
Erratum for Karaba et al., "Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment".
N/A
mBio
2024 Apr 10
6.5
1
20
38272241
N/A
2024 Apr
1
21
38335905
Convalescent plasma: An unexpected new therapeutic option for critically ill COVID-19 patients coming from the past.
N/A
J Clin Anesth
2024 Feb 8
2.74
1
22
38310906
Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2.
N/A
Lancet Infect Dis
2024 Feb 1
21.77
1
23
38048665
Fixation and reversion of mutations in the receptor-binding domain of SARS-CoV-2 spike protein.
N/A
Diagn Microbiol Infect Dis
2024 Feb
2.33
1
24
38297027
Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice.
N/A
Sci Rep
2024 Jan 31
4.12
1
25
36600579
N/A
2024 Jan 23
8